NCT00446082

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 85 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the pharmacokinetic profile and the safety/tolerability profile of single and monthly doses of pasireotide LAR intramuscular (i.m.) injection in patients with acromegaly and patients with carcinoid disease

Conditions

• Carcinoid Tumor
• Acromegaly

Interventions

Type	Name	Description
DRUG	Pasireotide

Timeline

• Start date: 2006-06-01
• Primary completion: 2013-11-01
• Completion: 2013-11-01
• First posted: 2007-03-12
• Last updated: 2020-12-21

Locations

17 sites across 6 countries: United States, Belgium, Canada, Germany, Netherlands, Norway